Search clinical trials for: Antithrombin III

Total 10434 results

Mitsubishi Tanabe Pharma GmbH

Completed

Safety of Argatroban Infusion in Conduction Disturbances (SAICoDis)

Stable Coronary Artery Disease (CAD) | Unstable Angina (Troponin Negative)

Germany
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Deep Vein Thrombosis | Pulmonary Embolism | Metastatic Malignant Solid Neoplasm | Cerebral Vein Thrombosis | Splanchnic Vein Thrombosis

United States
Bayer

Completed

A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin (RENOVATOR)

Non-valvular Atrial Fibrillation (NVAF)

Korea, Republic of
Second Affiliated Hospital, School of Medicine,...

Completed

Efficacy Argatroban in Ischemic Stroke With Early Deterioration (EASE) (EASE)

Acute Progressive Ischemic Stroke

China
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)

Healthy Volunteers
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)

Healthy Volunteers
McMaster University

Completed

Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery

Surgery | Venous Thromboembolism | Adherence, Medication | Prophylaxis | Neoplasms Malignant

Canada
General Hospital of Shenyang Military Region

Completed

Argatroban Plus R-tPA for Acute Ischemic Stroke

Stroke

China
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

Healthy

United States
Pfizer

Completed

Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants

Healthy

Belgium
GlaxoSmithKline

Completed

Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)

Thrombosis, Venous
Hamilton Health Sciences Corporation
Population Health Research Institute

Unknown

Apixaban Dose Reduction in Patients With Elevated Drug Levels (ADREL)

Atrial Fibrillation

Canada
University of Michigan

Withdrawn

Evaluation of Wound Drainage After Knee or Hip Arthroplasty

Complications; Arthroplasty

United States
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

Venous Thromboembolism

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, New Zealand, Poland, India, United States, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Taiwan, Brazil, Denmark, German... and more
Brigham and Women's Hospital
GlaxoSmithKline

Completed

Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism

Deep Vein Thrombosis | Pulmonary Embolism

United States
Peng Zhang

Recruiting

Neoadjuvant Therapy Combined With Radical Surgery for the Treatment of Small Cell Lung Cancer (SCLC) in II and IIIA Stage

Small-cell Lung Cancer

China
Azienda Ospedaliero Universitaria Maggiore della...

Recruiting

EdOxaban in fRagIle Patients With Percutaneous Endoscopic GAstrostoMy and atrIal fIbrIllation (ORIGAMI II)

Atrial Fibrillation | Fragility

Italy
Sohag University

Not yet recruiting

"ORBIT" Versus "HAS-BLED" Scores in Predicting Major Bleeding in Patients With Atrial Fibrillation Receiving Oral Anticoagulants.

Patients With Atrial Fibrillation Receiving Oral Anticoagulants
Yonsei University

Recruiting

AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)

Atrial Fibrillation Patients With Moderate or High Stroke Risk Who Had Undergone Catheter Ablation of Atrial Fibrillation

Korea, Republic of
The Second Affiliated Hospital of Chongqing Medical...

Not yet recruiting

A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation

Atrial Fibrillation | Left Atrial Appendage Thrombosis | Rivaroxaban
Bayer
Janssen Research & Development, LLC

Completed

Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function (XARETO)

Non-valvular Atrial Fibrillation (NVAF)

Taiwan
Bayer
Janssen Research & Development, LLC

Completed

Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban (EMIR)

Atrial Fibrillation

Spain
Portola Pharmaceuticals

Completed

An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects

Health Volunteers
Brigham and Women's Hospital

Completed

Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data

Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Xarelto [SPAF] Post-marketing Surveillance in Japan

Brain Ischemia

Japan
Georg Nickenig
Boehringer Ingelheim

Completed

Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation (ODIn-AF)

Atrial Fibrillation | Oral Anticoagulation | Cardioembolic Events

Germany
Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company

Completed

Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation

Atrial Fibrillation

United Kingdom
Bayer
Janssen Research & Development, LLC

Completed

Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation (XaMINA)

Atrial Fibrillation

Korea, Republic of, Taiwan
Hospital do Servidor Publico Estadual

Unknown

Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs. (DVT)

Deep Venous Thrombosis

Brazil
Hopital Lariboisière

Unknown

Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban (ECAN)

Coagulation Disorder | Non Valvular Atrial Fibrillation

France
Bristol-Myers Squibb
Pfizer

Terminated

Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter

Venous Thromboembolism

United States, Belgium, Canada, Mexico, Netherlands
Bayer
Janssen Research & Development, LLC

Completed

Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication (SATORI)

Venous Thrombosis

France
Bayer
Janssen Scientific Affairs, LLC

Completed

Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism (BOX-AF)

Atrial Fibrillation

Belgium
McMaster University

Terminated

Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia

Heparin-induced Thrombocytopenia

Canada
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer

Venous Thrombosis | Deep Vein Thrombosis

Italy, Austria, Brazil, Hungary, Netherlands, South Africa, Israel, Australia, Germany
Kurobe LLC

Completed

Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis

Bacterial Conjunctivitis

United States
Mountain Home Research & Education Corporation
Cubist Pharmaceuticals LLC; East Tennessee State University

Terminated

Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty

Staphylococcal Infections | Methicillin-resistant Staphylococcus Aureus

United States
Jilin University

Recruiting

Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction (ACTonLVT)

ST-segment Elevation Myocardial Infarction (STEMI) | Left Ventricular Thrombus

China
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR); Canadian Venous Thromboembolism...

Recruiting

COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation (COBRRA-AF)

Atrial Fibrillation

Canada
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR); Canadian Venous Thromboembolism...

Completed

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban (COBRRA Pilot)

Venous Thromboembolism

Canada
Bayer
Janssen Research & Development, LLC

Completed

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer (COSIMO)

Venous Thrombosis and Pulmonary Embolism

Italy, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Spain, Denmark, Australia
Scott C. Woller, MD
Bristol-Myers Squibb; University of Utah

Completed

Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome (ASTRO-APS)

Thrombosis | Antiphospholipid Syndrome

United States
Bayer
Janssen Scientific Affairs, LLC

Completed

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study (XASSURE)

Stroke

China
Perosphere Pharmaceuticals Inc, a wholly owned...
Quintiles, Inc.

Completed

Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban

Anticoagulation Reversal

United States
Boehringer Ingelheim

Completed

Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State

Healthy Volunteers

China
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin

Healthy
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II

Heparin-induced Thrombocytopenia Type II

France
NYU Langone Health
Guerbet

Completed

Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography

Coronary Artery Disease

United States
Boehringer Ingelheim

Completed

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects

Healthy

Japan
Merck Sharp & Dohme LLC

Completed

A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)

Thrombosis

3

Subscribe